HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Michael Roche, Martin R Jakobsen, Anne Ellett, Hamid Salimiseyedabad, Becky Jubb, Mike Westby, Benhur Lee, Sharon R Lewin, Melissa J Churchill, Paul R Gorry
Retrovirology | BIOMED CENTRAL LTD | Published : 2011
Related Projects (1)
Awarded by Australian Center for HIV and Hepatitis Virology Research
Awarded by NIH/NIAID
We thank J. Sodroski for providing pSVIII-YU2 Env plasmid and for providing pCMV Delta P1 Delta envpA and pHIV-1Luc plasmids. We also thank D. Kabat for providing JC53 cells, N. Shimizu and H. Hoshino for permission to use NP2-CD4/CCR5 cells, and D. Mosier and R. Nedellec for supplying the NP2-CD4/CCR5 cells. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.; U87-CD4/CCR5 cells from Dr. HongKui Deng and Dr. Dan R. Littman. This study was supported by a grant by the Australian Center for HIV and Hepatitis Virology Research (ACH2) to PRG and MJC, and by a grant from NIH/NIAID to BL (R21 AI092218). MR is supported by a Monash University Postgraduate Research Scholarship. PRG is the recipient of an Australian National Health and Medical Research Council (NHMRC) Level 2 Biomedical Career Development Award. SRL is the recipient of a NHMRC Practitioner Fellowship. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.